Human Treg responses allow sustained recombinant adeno-associated virus–mediated transgene expression
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors have shown promise for the treatment of several diseases; however, immune-mediated elimination of transduced cells has been suggested to limit and account for a loss of efficacy. To determine whether rAAV vector expression can persist long term, we administered rAAV vectors expressing normal, M-type α-1 antitrypsin (M-AAT) to AAT-deficient subjects at various doses by multiple i.m. injections. M-specific AAT expression was observed in all subjects in a dose-dependent manner and was sustained for more than 1 year in the absence of immune suppression. Muscle biopsies at 1 year had sustained AAT expression and a reduction of inflammatory cells compared with 3 month biopsies. Deep sequencing of the TCR Vβ region from muscle biopsies demonstrated a limited number of T cell clones that emerged at 3 months after vector administration and persisted for 1 year. In situ immunophenotyping revealed a substantial Treg population in muscle biopsy samples containing AAT-expressing myofibers. Approximately 10% of all T cells in muscle were natural Tregs, which were activated in response to AAV capsid. These results suggest that i.m. delivery of rAAV type 1-AAT (rAAV1-AAT) induces a T regulatory response that allows ongoing transgene expression and indicates that immunomodulatory treatments may not be necessary for rAAV-mediated gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regulatory T cells (Treg) modulate immune tolerance towards transgene product and capsid that are vital to durable expression of therapeutic protein (16, 17).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This long-term expression was attributed to the induction of regulatory T cells (Tregs) in the muscles of AAV-injected patients.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [11]
In the citing paper
“Tolerance induction and long-term expression of transgene in local muscle-directed AAV gene therapy was attributed to Tregs due to their ability to suppress immune responses [92].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
In the citing paper
“Infiltration of CD4+ forkhead box P3+ (FoxP3) T cells, in addition to CD8+ T cells, was reported in α1-antitrypsin (AAT) deficiency and Glybera studies [92, 93].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [92]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“The long-lasting presence of rAAV1 capsid may in some ways mimic a chronic viral infection, which has been shown to induce Treg responses (17) along with what has been termed “exhausted” T cells.”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 2×
“Interestingly, expression of PD-1 and PD-L1, which is associated with chronic viral infection and exhausted T cell responses (18–20), was also observed in many of the inflammatory foci of the rAAV-injected muscles.”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“(6), in a liver-directed hemophilia B trial, a modest immune modulation (60 mg prednisolone daily with tapering and discontinuation over 4 to 7 weeks) was sufficient to enhance gene expression and decrease transaminase elevation.”
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide
Jordan, M. S., Boesteanu, A., Reed, A. J., Petrone, A. L., Holenbeck, A. E., Lerman, M. A., Naji, A., & Caton, A. J. (2001) · Nature Immunology · doi:10.1038/86302 · Cited by 1,660 · cited 1×
“It is known that natural Tregs (CD4+CD25+FOXP3+) arise in the thymus during development and are thought to possess T cell receptors specific for self antigens (26).”
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Cited by
Items 101–171 of 171
Gernoux, G., Guilbaud, M., Devaux, M., Journou, M., Pichard, V., Jaulin, N., Léger, A., Duff, J. L., Deschamps, J., Guiner, C. L., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.003 · Cited by 14
“It has already been described in previous clinical trials, where sustained transgene expression was explained by the presence of immune cells mediating tolerance (Tregs and/or exhausted T cells) that were detected in periphery or at the site of injection.(39,41,48) In the present study, we analyzed the presence of mus…”
BackgroundInfluentialGruntman, A. M., Gernoux, G., Tang, Q., Ye, G., Knop, D. R., Wang, G., Benson, J. M., Coleman, K. E., Keeler, A. M., Mueller, C., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.013 · Cited by 13
“AAV8-VLP 1,775 (526) 203,595 (121,972) 239,328 (84,476) 980,443 (19,295) 6,534,063 (5,428,745) 2,070 (319) 5,353 (4,253) 131,755 (–)”
Self-citationZieger, M. V., Borel, F., Greer, C., Gernoux, G., Blackwood, M., Flotte, T. R., & Mueller, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.003 · Cited by 12
Self-citationReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer
Pandya, M., Britt, K., Hoffman, B. E., Ling, C., & Aslanidi, G. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000093 · Cited by 13
Vector-Mediated Antibody Gene Transfer for Infectious Diseases
Schnepp, B. C., & Johnson, P. R. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_8 · Cited by 11
Therapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency
Gruntman, A. M., & Flotte, T. R. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7163-3_27 · Cited by 13
Self-citationBanks, G. B., Chamberlain, J. S., & Odom, G. L. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009179 · Cited by 10
Chen, Y., Cheadle, C. E., Rice, L. V., Pfeffer, P., Dimeloe, S., Gupta, A. K., Bush, A., Gooptu, B., & Hawrylowicz, C. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.667203 · Cited by 10
“Additionally, findings from gene therapy studies demonstrate that low level secretion of AAT is sufficient to induce Treg responses in the local microenvironment, favouring toleration of the associated adeno-associated virus capsid (52).”
BackgroundPichard, V., Guilbaud, M., Devaux, M., Jaulin, N., Journou, M., Michée‐Cospolite, M., Garcia, A., Ferry, N., Michalak-Provost, S., Gernoux, G., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00514-z · Cited by 11
“Many gene transfer studies in liver but also in muscle using rAAV showed that tolerance to the transgene product could be achieved by the induction of antigen-speci fi c CD4 + CD25 + FoxP3 + regulatory T cells (Tregs) [23 – 25, 60, 61].”
Augmentation treatment for α1 antitrypsin deficiency
Crystal, R. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60036-8 · Cited by 9
Vitale, F., Ortolan, J., Volpe, B., Marambaud, P., Giliberto, L., & d'Abramo, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01003-7 · Cited by 8
Ferrand, M., Rocha, S. D., Corre, G., Galy, A. H. M., & Boisgérault, F. (2015) · Molecular Therapy · doi:10.1038/mt.2015.59 · Cited by 8
Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 9
Sherpa, C., & Grice, S. F. J. L. (2020) · Current HIV Research · doi:10.2174/1570162x18666200210121339 · Cited by 8
Journou, M., Devaux, M., Jaulin, N., Pichard, V., Segovia, M., Moreau, A., Duff, J. L., Cuturi, M. C., Guilbaud, M., & Adjali, O. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101409 · Cited by 8
“7,21,26,29,47 In the present study, we also observed in fi ltration of CD4 + FoxP3 + Tregs up to 5 years pi (Figure 7), and this might contribute to the persistence of transgene expression.”
InfluentialPharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases
Roychoudhury, P., Feelixge, H. S. D. S., Pietz, H. L., Stone, D., Jerome, K. R., & Schiffer, J. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw104 · Cited by 6
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
“Preclinical models will also have to reproduce the variability of the responses observed in humans [14,16,17].”
BackgroundOptogenetic Control of Muscles: Potential Uses and Limitations
Cohen, E. M., Knapman, F. L., & Bilston, L. E. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.236 · Cited by 5
“20 This means any immune suppression treatments must be administered cautiously, targeting specific pathways to prevent therapeutic rejection and promote transgene persistence.”
Immunohistochemistry Staining for Human Alpha-1 Antitrypsin
Fu, D., & Campbell‐Thompson, M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7163-3_13 · Cited by 5
Self-citationAlpha-1- Antitrypsin Deficiency Liver Disease: Science and Therapeutic Potential 50 Years Later
Teckman, J. H. (2014) · Journal of Gastroenterology Pancreatology & Liver Disorders · doi:10.15226/2374-815x/1/3/00113 · Cited by 5
“Christian Mueller presented new studies in the transgenic PiZ mouse model using recombinant Adeno-Associated Virus (rAAV) vector designed with both the WT M A1AT to provide synthesis of normal, physiologic amounts of M A1AT to prevent lung disease and containing anti-A1AT mutant Z miRNA to prevent liver disease [36-38…”
MethodExpanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy
Khan, G., & Hussain, M. S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128386290250507101412 · Cited by 4
Flotte, T. R., Daniels, E., Benson, J. M., Bevett-Rose, J. M., Cornetta, K. G., Diggins, M., Johnston, J., Sepelak, S., van der Loo, J. C. M., Wilson, J. M., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.170 · Cited by 4
Self-citationPham, Q. H., Bheemsetty, V. A., Nguyen, P. A., Samara-Kuko, E., Gao, F., Chuah, M., & VandenDriessche, T. (2025) · Human Gene Therapy · doi:10.1177/10430342251359989 · Cited by 3
“59,60 Detargeting ectopic expression in antigen-presenting cells may be an important determinant toward preventing or minimizing such transgene-speci fi c immunity.”
The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes
Simini, G., & Batty, P. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.028 · Cited by 3
Lei, C., Lü, W., Li, Y., yang, H., Zhang, K., Wang, N., Xuan, L., & Guo, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-22658-z · Cited by 3
“Christian Mueller and others have done a clinical study on recombinant adeno-associated virus (rAAV) 39 .”
Efficient LAMA1 Gene Activation by Epigenome Editing as a Therapeutic Approach for LAMA2-CMD
Qin, Y., Akbulut, T., Mandraju, R., Connolly, K., Bechill, J., Assadian, F., Foster, C., Shottek, A., Levy, S., Benoit, J. D., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342251401873 · Cited by 6
“In agreement with previous reports, muscle targeted AAV administration induced persistent FOXP3 + T cells in the muscle tissue, 14 indicating a counterbalance of immune response in the muscle tissue.”
Blackwood, M., Gruntman, A. M., Tang, Q., Pires-Ferreira, D., Reil, D., Kondratov, O., Marsic, D., Zolotukhin, S., Gernoux, G., Keeler, A. M., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101200 · Cited by 4
Self-citationAntipova, A. Y., & Lavrentieva, I. N. (2017) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-2017-1-7-20 · Cited by 3
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
Chan, Y. A., & Deverman, B. E. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_21 · Cited by 3
What Is Suppression of Anti–Adeno-Associated Virus Capsid T-Cells Achieving?
Flotte, T. R., & Mueller, C. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2506 · Cited by 4
“Perhaps more informative is the recent finding that rAAV1-AAT elicits an AAV capsid-spe-cific regulatory T-cell (T reg ) response (Mueller et al ., 2013), which was documented both in situ and in the peripheral blood.”
Self-citationStrategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Surgical and Bronchoscopic Lung Volume Reduction Treatment for α-1 Antitrypsin Deficiency
Rokadia, H. K., & Stoller, J. K. (2015) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000116 · Cited by 2
Development of Next-Generation Muscle Gene Therapy AAV Vectors
Nance, M. E., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_11 · Cited by 2
Muscle-Directed Gene Therapy for Alpha-1 Antitrypsin Deficiency
Gruntman, A. M., & Flotte, T. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_45 · Cited by 2
Self-citationTurner, A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803942-7.00014-3 · Cited by 2
Flotte, T. R., Blackwood, M., Arjomandnejad, M., Harkins, A. L., Sylvia, K., Iyer, S., Kokoski, D., Artinian, R., & Keeler, A. M. (2025) · medRxiv · doi:10.1101/2025.05.07.25327170 · Cited by 3
Self-citationThe Responsible Development of Adeno-Associated Virus Gene Therapies
Wilson, J. M., & Caplan, A. L. (2025) · Human Gene Therapy · doi:10.1177/10430342251359668 · Cited by 2
Self-citationPires-Ferreira, D., Reil, D., Tang, Q., Blackwood, M., Gallagher, T. F., Keeler, A. M., Chichester, J. A., Vyhnal, K. K., Lindborg, J. A., Benson, J. M., et al. (2024) · Genes · doi:10.3390/genes15091188 · Cited by 2
Self-citationAlpha-1 Antitrypsin Deficiency in Children. A Modern View of the Problem
Вениаминовна, В. И., Fedotova, G., Timofeevа, M. S., & Timofeev, E. S. (2024) · Ural Medical Journal · doi:10.52420/umj.23.6.132 · Cited by 1
Käyhty, P., Nieminen, T., Eriksson, R. A. E., Tumelius, R., Tawfek, A., Laidinen, S., Ruotsalainen, A., Bailey, A., Galibert, L., Lesch, H. P., et al. (2026) · Gene Therapy · doi:10.1038/s41434-025-00588-9 · Cited by 1
“Disease-associated in fl ammation can increase transgene immunogenicity [17], although in some cases, IM gene transfer may promote a tolerogenic environment by promoting the activation and accumulation of regulatory T cells (Tregs) [22].”
Bruce-Hickman, D., Greene, C. M., & Gooptu, B. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018214 · Cited by 1
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Immune Responses to Adeno-Associated Virus-Mediated CRISPR Therapy
Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29193.amk · Cited by 1
“…has been shown to be tolerogenic, inducing T-regulatory cells and providing long-lived transgene expression in clinical trials of AAT deficiency 12–16 and lipoprotein lipase (LPL) deficiency, 17–19 in proinflammatory environments, similar to those associated with dystrophies, muscle-specific…”
Meeting Summary: ESGCT 2022 AAV Safety Plenary Session
Gallagher, T. F. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29230.tga · Cited by 1
“6,7 Strategies are being developed to counter effector T cell responses, including generation of capsid-specific chimeric antigen receptor Tregs.”
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Greulich, T. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_33
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
“…que la présence de lymphocytes T CD8 + spécifiques de la capside n’influait pas forcément sur le maintien à long terme du transgène suite à l’injection de vecteur AAV recombinant dans le muscle, corrélant avec la présence de Tregs également spécifiques de la capside (Mueller et al., 2013). iii.”
BackgroundNicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
[A review of gene therapy for Duchenne muscular dystrophy].
Dong, Q.-C., Chen, H., & Jin, X. (2018) · PubMed Central · doi:10.7499/j.issn.1008-8830.2018.08.017
Greulich, T., & Veith, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-63651-0_35
Brèves: Adénovirus et déficit en AAT
(2014) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(14)72345-7
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
AAV-based TCAP delivery rescues mitochondria dislocation in limb-girdle muscular dystrophy R7
Lv, X., Liu, S., Li, X., Lv, H., Shao, K., Luo, S., Zhao, D., Yan, C., & Lin, P. (2024) · Brain · doi:10.1093/brain/awae351
Even a Worm Will Turn: Immunity Following AAV Vector Administration
Patel, K., Khatri, A., & Somanathan, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_7
Self-citationCaractérisation et immunomodulation de la réponse cellulaire contre les produits de thérapie génique
Avenel, A. (2024) · theses.fr (ABES) · doi:10.70675/f4cd9ee5z09e6z4e26z8edazf0770a51f57c
Keeler, A. M., Flotte, T. R., Blackwood, M., Arjomandnejad, M., Harkins, A. L., Sylvia, K., Iyer, S., Kokoski, D., & Artinian, R. (2025) · Research Square · doi:10.21203/rs.3.rs-6431041/v1
Self-citationPezet, S., Hua, J., Marais, T., Delamare, M., Elouej, S., Lemos, J. P., Castiglione, A., Astord, S., Cohen-Tannoudji, M., Pêche, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682744
Decoupling Efficacy from Toxicity: Engineering Spatial Control in AAV-Mediated Gene Therapy
Fan, Y., Tan, K., Chen, H., Chen, X., Pan, Y., Chen, Y., Ao, Y., Bu, Y., & Li, H. (2026) · Molecular Therapy Advances · doi:10.64898/2025.12.26.696588
Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion
Gwalani, L. A., Park, M., Ysasi, A. B., Motwani, M., Jackson, R., Bu, J., Luo, Z., Bladon, J. H., Pfister, E. L., Mueller, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.019 · Cited by 1
“22 Tregs are a subset of CD4 + T cells that play a key role in maintaining immune homeostasis and preventing autoimmune diseases.”
Self-citationCharacterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Kaur, P., Vancha, H., Pal, B., Garg, P., Pamu, S., Yanadaiah, J. P., Sadhu, N. K., Deepa, M., & Yanadaiah, P. (2026) · Human Gene · doi:10.1016/j.humgen.2026.201571
Jeanpierre, L., Pecquet, C., Saliba, H., Finard, P., Terry, S., Tavella, G., Guesmia, I., Boutin, S., Bertin, B., Benkhelifa‐Ziyyat, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202541
“…ubiquitous PGK promoter (AAV1-OVA 257 ), was selected as the transgene, enabling CD8 + T cell activation to be analyzed independently of potential confounding factors such as anti-transgene CD4 + responses, antibody-mediated enhancement of CD8 + activation (23), or CD4 + regulatory T cells (31–33).”
Metadata
- Authors
- Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., Campbell-Thompson, M., Fu, A. D., Yachnis, A., Knop, D. R., Ye, G.-J., Brantly, M., Calcedo, R., Somanathan, S., Richman, L. P., Vonderheide, R. H., Hulme, M. A., Brusko, T. M., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Applied Genetic Technologies (United States) (US)
- Cincinnati Children's Hospital Medical Center (US)
- National Jewish Health (US)
- Beaumont Hospital (IE)
- University of Florida Health (US)
- University of Pennsylvania (US)
- Corresponding author
- Flotte, Terence R.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-11-15
- Volume
- 123
- Issue
- 12
- Pages
- 5310-5318
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3859421
- OpenAlex
- W2087513462
- Cited by
- 169
- References
- 40
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 9 · 2021: 19 · 2020: 9 · 2019: 16 · 2018: 10 · 2017: 23 · 2016: 11 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000161)
- U.S. Food and Drug Administration (R01FD003896)
- National Heart, Lung, and Blood Institute (R01HL069877, HL 69877)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus, AAV1, alpha-1 antitrypsin deficiency, regulatory T cells, natural regulatory T cells, transgene expression persistence, gene therapy, T cell receptor V beta repertoire, AAV capsid, intramuscular injection, immunomodulation, muscle fibers
- MeSH terms
- Dependovirus, alpha 1-Antitrypsin, Biopsy, Capsid, Clone Cells, Gene Expression Regulation, Genetic Vectors, Humans, Injections, Intramuscular, Lymphocyte Activation, Recombinant Fusion Proteins, Genetic Therapy, Gene Rearrangement, beta-Chain T-Cell Antigen Receptor, Receptors, Antigen, T-Cell, alpha-beta, Muscle, Skeletal, Transgenes, alpha 1-Antitrypsin Deficiency, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.